Optic neuritis is an inflammatory demyelinating disorder of the optic nerve that typically causes acute painful vision loss and can be associated with multiple sclerosis or other inflammatory disorders.
Phase 3 trial data show daratumumab reduced relapse risk by 74% in NMOSD. Separately, the FDA accepted an NDA for iberdomide plus daratumumab/dexamethasone in relapsed/refractory multiple myeloma, with a PDUFA date of August 17, 2026.
Over 10 companies are developing 12+ pipeline therapies for Neuromyelitis Optica Spectrum Disorder, including Roche's satralizumab Phase III pediatric trial and multiple anti-CD20 monoclonal antibody candidates.
Ocular Therapeutix's Axpaxli outperformed low-dose Eylea in a Phase 3 trial for wet AMD, while Oculis Holding reported narrowed Q4 losses and expects Phase 3 trial readouts for OCS-01 in Q2 2026.
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT07704294 |
Early Prediction of Outcomes Following Optic Neuritis: Development and Acceptability of a Prognostic Tool |
NOT_YET_RECRUITING | |
| NCT07623668 |
Privosegtor Investigation in Optic Neuropathies Efficacy Evaluation Research |
RECRUITING | PHASE3 |
| NCT07623252 |
Prospective Evaluation of the 2022 Optic Neuritis Criteria When Optic Neuritis Is Suspected |
RECRUITING | |
| NCT07100990 |
Treatment of Inflammatory Myelitis and Optic Neuritis With Early vs Rescue Plasma Exchange (TIMELY-PLEX) |
RECRUITING | PHASE3 |
| NCT06916182 |
Evaluation of Optic Neuritis Using Synthetic Quantitative MRI |
NOT_YET_RECRUITING | |
| NCT06453694 |
Efgartigimod for the Treatment of Acute Optic Neuritis |
RECRUITING | PHASE2 |
| NCT06390579 |
Building Research With Artificial Intelligence in Neuro-Ophthalmology |
COMPLETED | |
| NCT06389968 |
Light Stimulation to Improve Visual Function After Optic Neuritis in Persons with Multiple Sclerosis |
RECRUITING | NA |
| NCT05605951 |
Acute Optic Neuritis Network: an International Study That Invesitages Subjects With a First-ever Episode of Acute Inflammation of the Optic Nerve |
RECRUITING | |
| NCT05540262 |
Edaravone in the Treatment of Optic Neuritis |
RECRUITING | NA |
